Omega Therapeutics, Inc. - COMMON STOCK (OMGAQ)

CUSIP: 68217N105

Q4 2022 13F Holders as of 31 Dec 2022

Security identity
Shares outstanding
55,351,475
Holder snapshot
Share change
+66,981
Put/Call ratio
102%
Reported price per share
$5.71
Number of holders
46
Value change
+$387,343
Number of buys
19
Number of sells
14

Security key

68217N105

Report period

Q4 2022

Institutions

46

Top holders

10

Ownership snapshot

Top reported holders of OMGAQ - Omega Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Lead holder
13D/G signal
Evidence rows
0
Latest as of
No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.

13F holder rows

Institutional holders as of Q4 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
46
Shares
16,768,091
Rows available
46
Investor Option Weight % Change % Reported value * Price Shares Share Change Activity Report Period

* Reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that failed the local validity check.

Compare Q4 2022 vs Q3 2022 Across Filers

Q3 2022 holders
40
Q4 2022 holders
46
Holder diff
6
Investor Q3 2022 Shares Q4 2022 Shares Share Diff Share Chg % Q3 2022 value Q4 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .